Skip to content

Study · Randomized controlled trial · n = 50 · 2026

8 results

Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.

Schacht JP, Sakai JT, Raymond K, Shelton R

The American journal of psychiatry29 Jul 2026Cited by 4 (Europe PMC)

PMID42522065 (opens in a new tab)PMCIDPMC13567346 (opens in a new tab)DOI10.1176/appi.ajp.20260003 (opens in a new tab)PepBankPUB-42522065
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with alcohol use disorder, oral semaglutide did not significantly reduce laboratory-assessed alcohol craving versus placebo.

    In plain wordsIn adults with alcohol use disorder, oral semaglutide did not significantly reduce alcohol craving in the lab compared with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeLaboratory-assessed alcohol cue-elicited craving at week 6
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    3 mg/day for 4 weeks, then 7 mg/day for 4 weeks · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide did not significantly reduce laboratory-assessed craving or drinks per day compared with placebo
    3 context sentences
    Summary · context
    The primary outcome was laboratory-based alcohol cue-elicited craving at week 6.
    Summary · context
    This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD).
    Summary · context
    Fifty individuals with moderate to severe AUD were randomized to receive semaglutide (3 mg/day for 4 weeks, then 7 mg/day for 4 weeks) or placebo for 8 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with alcohol use disorder, oral semaglutide did not significantly reduce drinks per day versus placebo.

    In plain wordsIn adults with alcohol use disorder, oral semaglutide did not significantly reduce drinks per day compared with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeDrinks per day
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    3 mg/day for 4 weeks, then 7 mg/day for 4 weeks · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide did not significantly reduce laboratory-assessed craving or drinks per day compared with placebo
    3 context sentences
    Summary · context
    Key preregistered secondary outcomes were heavy drinking days and drinks per day during the last 4 weeks of treatment.
    Summary · context
    This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD).
    Summary · context
    Fifty individuals with moderate to severe AUD were randomized to receive semaglutide (3 mg/day for 4 weeks, then 7 mg/day for 4 weeks) or placebo for 8 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with alcohol use disorder, oral semaglutide significantly reduced heavy drinking days versus placebo.

    In plain wordsIn adults with alcohol use disorder, oral semaglutide reduced the number of heavy drinking days compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseHeavy drinking days
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    3 mg/day for 4 weeks, then 7 mg/day for 4 weeks · oral · 8 weeksAs given in this study (human).

    Measurements

    b
    −0.58
    heavy drinking days

    Source sentences

    Summary
    but significantly reduced heavy drinking days (b=-0.580, 95% CI=-1.012, -0.148).
    3 context sentences
    Summary · context
    Key preregistered secondary outcomes were heavy drinking days and drinks per day during the last 4 weeks of treatment.
    Summary · context
    This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD).
    Summary · context
    Fifty individuals with moderate to severe AUD were randomized to receive semaglutide (3 mg/day for 4 weeks, then 7 mg/day for 4 weeks) or placebo for 8 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with alcohol use disorder, oral semaglutide significantly reduced drinks per drinking day versus placebo.

    In plain wordsIn adults with alcohol use disorder, oral semaglutide reduced drinks per drinking day compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseDrinks per drinking day
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    3 mg/day for 4 weeks, then 7 mg/day for 4 weeks · oral · 8 weeksAs given in this study (human).

    Measurements

    b
    −1.177
    drinks per drinking day

    Source sentences

    Summary
    Semaglutide also significantly reduced drinks per drinking day (b=-1.177, 95% CI=-2.307, -0.047)
    2 context sentences
    Summary · context
    This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD).
    Summary · context
    Fifty individuals with moderate to severe AUD were randomized to receive semaglutide (3 mg/day for 4 weeks, then 7 mg/day for 4 weeks) or placebo for 8 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with alcohol use disorder, oral semaglutide significantly reduced naturalistic alcohol craving versus placebo.

    In plain wordsIn adults with alcohol use disorder, oral semaglutide reduced everyday alcohol craving compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseNaturalistic alcohol craving
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    3 mg/day for 4 weeks, then 7 mg/day for 4 weeks · oral · 8 weeksAs given in this study (human).

    Measurements

    b
    −2.195
    naturalistic alcohol craving

    Source sentences

    Summary
    naturalistic alcohol craving (b=-2.195, 95% CI=-4.174, -0.216)
    2 context sentences
    Summary · context
    This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD).
    Summary · context
    Fifty individuals with moderate to severe AUD were randomized to receive semaglutide (3 mg/day for 4 weeks, then 7 mg/day for 4 weeks) or placebo for 8 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with alcohol use disorder, oral semaglutide significantly reduced cannabis use days versus placebo.

    In plain wordsIn adults with alcohol use disorder, oral semaglutide reduced the number of cannabis use days compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseCannabis use days
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    3 mg/day for 4 weeks, then 7 mg/day for 4 weeks · oral · 8 weeksAs given in this study (human).

    Measurements

    b
    −1.434
    cannabis use days

    Source sentences

    Summary
    cannabis use days (b=-1.434, 95% CI=-2.568, -0.301)
    2 context sentences
    Summary · context
    This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD).
    Summary · context
    Fifty individuals with moderate to severe AUD were randomized to receive semaglutide (3 mg/day for 4 weeks, then 7 mg/day for 4 weeks) or placebo for 8 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with alcohol use disorder, oral semaglutide reduced alcohol-related consequences at a significantly greater rate than placebo.

    In plain wordsIn adults with alcohol use disorder, oral semaglutide reduced alcohol-related problems faster than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseAlcohol-related consequences
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    3 mg/day for 4 weeks, then 7 mg/day for 4 weeks · oral · 8 weeksAs given in this study (human).

    Measurements

    b
    −4.618
    alcohol-related consequences

    Source sentences

    Summary
    Semaglutide reduced alcohol-related consequences at a significantly greater rate than placebo (b=-4.618, 95% CI=-8.651, -0.585).
    2 context sentences
    Summary · context
    This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD).
    Summary · context
    Fifty individuals with moderate to severe AUD were randomized to receive semaglutide (3 mg/day for 4 weeks, then 7 mg/day for 4 weeks) or placebo for 8 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with alcohol use disorder, significantly more participants on oral semaglutide than on placebo reduced their risk drinking level by one or more levels.

    In plain wordsIn adults with alcohol use disorder, more people on oral semaglutide than on placebo moved to a lower risk drinking level.

    Peptide
    Semaglutide
    Outcome
    IncreaseReduction in WHO risk drinking level
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    3 mg/day for 4 weeks, then 7 mg/day for 4 weeks · oral · 8 weeksAs given in this study (human).

    Measurements

    Wald chi-square
    4.01
    risk drinking level reduction

    Source sentences

    Summary
    Significantly more participants in the semaglutide group than the placebo group reduced their risk drinking level by one or more levels (Wald χ2=4.01).
    2 context sentences
    Summary · context
    This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD).
    Summary · context
    Fifty individuals with moderate to severe AUD were randomized to receive semaglutide (3 mg/day for 4 weeks, then 7 mg/day for 4 weeks) or placebo for 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.